BioSpace News Archive

3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%. Maximal efficacy expected at 6 to 8 weeks.

The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB

Transaction Enables an Immediate Acceleration of Clinical, Manufacturing and Commercial Investments Towards Kodiak’s “2022 Vision”

Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announced that Executive Directors of the company will present at several reputed international conferences in December.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the following upcoming investor conference:

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada through a subsidiary, to evaluate the combination of Seattle Genetics’ and Astellas’ antibody-drug conjugate (ADC) enfortumab vedotin and Merck’s anti-PD-1 therapy, KEYTRUDA®

First Off-the-Shelf Thoraco-abdominal Stent Graft with Pre-Cannulated Inner Branch Technology [02-December-2019] ATLANTA , Dec. 2, 2019 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-nside TAAA multibranch stent graft system for the endovascu

CVS Pharmacy, the retail division of CVS Health, announced that it has completed the rollout of time delay safes in all of its 375 CVS Pharmacy locations in North Carolina, including pharmacies located in Target stores.

CryoLife, Inc., announced it has received CE Mark for the E-nya thoracic stent graft system for the minimally invasive repair of lesions of the descending thoracic aorta, including thoracic aortic aneurysms and dissections.